Validation: Siraj Ahmed Dakhil, Ali Anwar Aboalola, Adham Abdulmajeed Niyazi, Mohammed Haytham Mawardi
The company says the beverage, created by industry experts and patented, is slated for a direct-to-consumer launch in December 2023
Still, tirzepatide as a molecule has also shown strong weight-management outcomes and is FDA-approved for that purpose under the Zepbound brand
Compared to that other weight-loss pill, which is sold under the brand name Contrave, semaglutide was linked to more than four times the risk of bowel obstruction, which prevents food from passing through the small or large intestine, resulting in symptoms such as nausea and vomiting, the study found
The FDA Adverse Event Reporting System (FAERS) informs future decisions about drugs
I have noticed a difference with my energy level